Cantargia står inför ett avgörande år med viktiga milstolpar redan under innevarande kvartal.
Nettoomsättningen uppgick till 231,2 MSEK (219,5), vilket motsvarade en ökning med 5,3 procent y-o-y...
Redeye leaves a comment following Lipum’s announcement of positive top-line results from the phase I...
Redeye comments on the positive results from a US study of melfufen in the intended target populatio...
Redeye saw a Q4 report showing sales above our estimates, with a total growth of 49% for the quarter...
Redeye returns following Kancera's Q4 report. We note that 2025 is shaping up to be a pivotal year, ...
FLOW väcker redan stort intresse Xoma har på kort tid inlett tre testprojekt med svenska företag ino...
TH1NG has received a termination notice for two bridge loans totalling SEK14m from Skellefteå Krafta...
Continued sequential improvements across the board '25e sales down 5% on lowered Ovzon-3 assumptions...
On 21 February, hackers stole about USD1.5bn in crypto assets from Bybit, a Dubai-based crypto excha...
Q4 sales +25% y-o-y, +4% q-o-q, FCF positive We expect new OEM partnerships to ramp up towards end '...
Redeye is only making rather small changes to forecasts and valuation following the full year report...
AcuCort har publicerat bolagets delårsrapport för det fjärde kvartalet 2024.
Redeye comments on Cantargia's Q4 report. The company faces a major catalyst in the first placebo-co...
Redeye comments on the outcome of Freemelt’s rights issue.
Redeye is positive about the HOVON study starting recruitment and provides a brief comment.
Weak market coupled with portfolio rebalancing headwinds We lower '25e-'26e EBIT by 4-3% Poised for ...
Redeye provides an updated view on Xbrane following its year-end report, which showed continued grow...
Redeye saw a report with sales that were lower than our expectations.
Redeye states Safello’s order volume was higher than Redeye Research estimates (RRe), while the aver...
